ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
Gujarat Themis Biosyn Limited has fixed September 23, 2026, as the record date for determining member entitlement for the final dividend for FY 2025-26.
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
Gujarat Themis Biosyn Limited announced the allotment of non-convertible debt securities. The filing serves as a regulatory disclosure regarding the issuance of these instruments.
Gujarat Themis Biosyn Ltd has submitted its quarterly shareholding pattern. This filing is a routine disclosure mandated by SEBI regulations.
The board of Gujarat Themis Biosyn approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹585 Crore on a private placement basis.
Gujarat Themis Biosyn Ltd has scheduled a board meeting for September 10, 2026, to consider raising funds through the private placement of non-convertible debentures.
Gujarat Themis Biosyn Limited has filed its Integrated Annual Report for the FY 2025-26 in compliance with SEBI LODR regulations.
Gujarat Themis Biosyn Limited issued a notice for its 45th Annual General Meeting scheduled for September 30, 2026, to transact various ordinary and special business items.
GTBL reported strong Q1FY27 growth with 22.1% revenue and PAT increases, driven by sales volumes. Strategy is shifting toward becoming an integrated fermentation-led CDMO via major acquisitions and API forward integration.
GTBL reported strong Q1 FY27 results with 22.1% revenue growth and 49.4% EBITDA growth. Strategy focuses on global CDMO expansion through acquisitions and forward integration into API production.
Gujarat Themis Biosyn Ltd reported revenue from operations of ₹43.8 Cr (+22.0% YoY) and net profit of ₹11.1 Cr (+22.0% YoY) for Q1 FY27.
GTBL is transforming into a global CDMO platform via acquisitions of MicroBiopharm Japan and Sanofi's anti-TB portfolio. FY26 revenue stood at INR 16,582 Lakhs with a 45.55% EBITDA margin.
Gujarat Themis Biosyn Limited reports Q4 FY26 revenue of ₹44.23 cr (+17.2% YoY) and PAT of ₹10.89 cr. Management announced two major inorganic acquisitions to pivot towards a CDMO model.
Gujarat Themis Biosyn Ltd reported revenue from operations of ₹44.2 Cr (+17.2% YoY) and net profit of ₹10.9 Cr (-9.2% YoY) for Q4 FY26.
Gujarat Themis Biosyn (GTBL) announced the acquisition of 100% of MicroBiopharm Japan (MBJ) for JPY 21.5 Bn (~INR 1,300 Cr), transitioning GTBL into a globally integrated fermentation-based CDMO.